- Follicular Lymphoma (FL) is one of the most common types of blood cancer, accounting for 20–25% of all non-Hodgkin lymphomas (NHL). Each year, approximately 15,000 new cases are diagnosed in the United States and 2,000 in Spain.

- Despite the disease’s biological diversity, most patients still receive similar treatment approaches, and relapse remains common.

- A new global alliance, led by Dr. Ari Melnick, Director of the Josep Carreras Leukaemia Research Institute, will unite leading research teams from the United States and Spain to develop innovative diagnostic tools and treatment strategies for patients with FL.

- This international initiative is supported by Blood Cancer United®—formerly The Leukemia & Lymphoma Society—and the Institute for Follicular Lymphoma Innovation (IFLI) through the Research Accelerator for Follicular Lymphoma (RAFL) Synergistic Team Award (STA).

This study systematically assessed GI cancer risks during working-age period (15–64 years) across 204 countries from 1990 to 2021. Key findings: (1) In 2021, approximately 1 in 46 individuals developed and 1 in 73 died from GI cancers during working age globally; (2) Colorectal cancer showed the highest incidence risk (0.91%), while gastric cancer had the highest mortality risk (0.35%); (3) Males faced approximately twofold higher risks than females, with East Asia and Mongolia exhibiting the highest regional and national risks, and ages 40–64 representing the high-risk period; (4) Despite overall declining trends, colorectal cancer incidence risk continued to rise. These findings provide evidence-based insights for developing targeted screening strategies.

A new study published in eGastroenterology uncovers profound alterations in the mucosal DNA and RNA virome and their interplay with host transcriptomes in colorectal polyps. The research team, led by Dr. Howard Yim and Dr. Xiaotao Jiang at the Microbiome Research Centre, UNSW, analyzed paired polyp and normal mucosal biopsies, revealing reduced viral diversity and distinct enrichment of Poxviridae, Retroviridae, and BeAn 58058 virus. These viral changes correlated with altered gene expression related to cancer and immune pathways, suggesting potential virome-driven mechanisms in early colorectal tumorigenesis.

Antimicrobial peptides (AMPs) exhibit broad-spectrum antimicrobial activity, low propensity to induce bacterial resistance, and multifunctional properties including immunomodulation and tissue regeneration promotion.This study comprehensively reviews the classification, antimicrobial mechanisms, and therapeutic applications of AMPs in major oral diseases such as dental caries, periodontitis, oral cancer, oral candidiasis, and oral mucositis. The research also analyzes key challenges in clinical translation (stability, cytotoxicity, immunogenicity, production costs) and corresponding solutions, while exploring their applications in implant coatings, oral dressings, combination therapy, and diagnostic markers, providing a robust theoretical basis for advancing oral disease treatment.

A discovery from Australian researchers could lead to better treatment for children with neuroblastoma, a cancer that currently claims 9 out of 10 young patients who experience recurrence. The team at the Garvan Institute of Medical Research in Sydney found a drug combination that can bypass the cellular defences these tumours develop that lead to relapse.